Fluidigm Underwriters Exercise Over-allotment Option | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluidigm today said that the underwriters for its initial public offering have exercised their over-allotment option, purchasing an additional 833,750 shares of the firm's common stock for $13.50 per share.

Fluidigm went public last week, selling 5,558,333 shares of common stock at a price of $13.50 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.